ALD403
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | CGRPR |
| Clinical data | |
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1644539-04-7 |
ALD403 is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP) as an antagonist.[1] It is currently in Phase III clinical trials.[2]
References
- ↑ Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013.
- ↑ "Pipeline". Alder Biopharmaceuticals.
This article is issued from Wikipedia - version of the 9/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.